Clinical potential of apremilast in the treatment of psoriatic arthritis

References

• NameyTCWrightVMollJMSeronegative PolyarthritisAmsterdam and New YorkNorth Holland Publishing Co1976
   Google Scholar
• GladmanDDPsoriatic arthritisHarrisEDBuddRCFiresteinGSKelly’s Textbook of Rheumatology7th edPhiladelphia, PAWB Saunders Co200511551164
   Google Scholar
• O’RiellyDDRahmanPGenetics of susceptibility and treatment response in psoriatic arthritisNat Rev Rheumatol2011771873222064628
   PubMed Web of Science ®Google Scholar
• MameliACauliATaccariEAssociation of MICA alleles with psoriatic arthritis and its clinical forms. A multicenter Italian studyClin Exp Rheumatol20082664965218799098
   PubMed Web of Science ®Google Scholar
• PaladiniFTaccariEFiorilloMTDistribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathiesArthritis Rheum2005523319332116200572
   PubMed Web of Science ®Google Scholar
• PitzalisCCauliAPipitoneNCutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritisArthritis Rheum1996391371458546722
   PubMed Web of Science ®Google Scholar
• CauliAPitzalisCYanniGHawadMPanayiGSCD1 positive antigen presenting cells in psoriatic and rheumatoid arthritisRheumatology2000666667310888713
   PubMed Web of Science ®Google Scholar
• CauliAMathieuATh17 and interleukin 23 in the pathogenesis of psoriatic arthritis and spondyloarthritisJ Rheumatol Suppl2012897151822751583
   PubMedGoogle Scholar
• RitchlinCTKavanaughAGladmanDDTreatment recommendations for psoriatic arthritisAnnals Rheu Dis20096813871394
   PubMed Web of Science ®Google Scholar
• SalvaraniCPipitoneNMarchesoniARecommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for RheumatologyClin Exp Rheumatol201129S28S4121906425
   PubMed Web of Science ®Google Scholar
• CleggDORedaDJMejiasEComparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative StudyArthritis Rheum199639201320208961906
   PubMed Web of Science ®Google Scholar
• KaltwasserJPNashPGladmanDEfficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trialArthritis Rheum2004501939195015188371
   PubMed Web of Science ®Google Scholar
• OlivieriISalvaraniCCantiniFTherapy with cyclosporine in psoriatic arthritisSemin Arthritis Rheum19972736439287388
   PubMed Web of Science ®Google Scholar
• SalvaraniCMacchioniPOlivieriIA comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritisJ Rheumatol2001282274228211669169
   PubMed Web of Science ®Google Scholar
• KingsleyGHKowalczykATaylorHA randomized placebo-controlled trial of methotrexate in psoriatic arthritisRheumatology2012511368137722344575
   PubMed Web of Science ®Google Scholar
• ContiMRichterWMehatsCLiveraGParkJYJinCCyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signalingJ Biol Chem20032785493549612493749
   PubMed Web of Science ®Google Scholar
• HouslayMDSchaferPZhangKYKeynote review: phosphodiesterase-4 as a therapeutic targetDrug Discov Today2005101503151916257373
   PubMed Web of Science ®Google Scholar
• ShepherdMCBaillieGSStirlingDIHouslayMDRemodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cellsBr J Pharmacol200414233935115066910
   PubMed Web of Science ®Google Scholar
• HeystekHCThierryA-CSoulardPMoulonCPhosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacityInt Immunol20031582783512807821
   PubMed Web of Science ®Google Scholar
• TenorHHedbomEHauselmannHJSchudtCHatzelmannAPhosphodiesterase isoenzyme families in human osteoarthritis chondrocytes – functional importance of phosphodiesterase 4Br J Pharmacol200213560961811834608
   PubMed Web of Science ®Google Scholar
• MoriFPerez-TorresSDe CaroRThe human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4DJ Chem Neuroanat201040364220347962
   PubMed Web of Science ®Google Scholar
• ClaveauDChenSLO’KeefeSPreferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitorJ Pharmacol Exp Ther200431075276015082748
   PubMed Web of Science ®Google Scholar
• EiglerASiegmundBEmmerichUBaumanKHHartmannGEndresSAnti-inflammatory activity of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF productionJ Leukoc Biol1998631011079469479
   PubMed Web of Science ®Google Scholar
• SchaferPHPartonAGandhiAKApremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasisBr J Pharmacol201015984285520050849
   PubMed Web of Science ®Google Scholar
• SchettGWollenhauptJPappKOral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled studyArthritis Rheum2012643156316722806399
   PubMed Web of Science ®Google Scholar
• KavanaughAMeasePJGomez-ReinoJJApremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trialProceedings of the Annual Scientific Meeting of the American College of Rheumatology (ACR/ARHP)November 9–14, 2012Washington, DC, USA abst L13
   Google Scholar
• KavanaughAMeasePJAdebajoAOLong-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritisProceedings of the 14th Annual European League Against Rheumatism (EULAR)June 12–15, 2013Madrid, Spain abst LB0001
   Google Scholar
• GladmanDDMeasePJKavanaughAAdebajoAOGomez-ReinoJJWollenhauptJApremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase 3, randomized, controlled trialsProceedings of the annual scientific meeting of the American College of Rheumatology (ACR/ARHP)October 25–30, 2013San Diego, CA, USA abst 0816
   Google Scholar
• MeasePJKavanaughAAdebajoAOApremilast: pooled safety analysis of three Phase 3, randomized, controlled trials in patients with psoriatic arthritisProceedings of the annual scientific meeting of the European League Against Rheumatism (EULAR)June 12–15, 2013Madrid, Spain abst SAT0299
   Google Scholar
• MeasePJKavanaughAGladmanDDLong-term safety and tolerability of Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trialsProceedings of the annual scientific meeting of the American College of Rheumatology (ACR/ARHP)October 25–30, 2013San Diego, CA, USA abst 310
   Google Scholar
• CutoloMMyersonGEFleischmannRMLong term (52 week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2)Proceedings of the annual scientific meeting of the American College of Rheumatology (ACR/ARHP)October 25–30, 2013San Diego, CA, USA abst 815
   Google Scholar
• EdwardsCJBlancoFJCrowleyJHuCStevensRMBirbaraCALong term (52 week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3)Proceedings of the annual scientific meeting of the American College of Rheumatology (ACR/ARHP)October 25–30, 2013San Diego, CA, USA abst 311
   Google Scholar
• WellsAFEdwardsCJAdebajioAOApremilast in the treatment of DMARD-Naïve psoriatic arthritis patients: results of a phase 3 randomized, controlled trial (PALACE 4)Proceedings of the annual scientific meeting of the American College of Rheumatology (ACR/ARHP)October 25–30, 2013San Diego, CA, USA abst L4
   Google Scholar
• Heuft-DorenboschLSpoorenbergAvan TubergenALandewéRvan der TempelHMielantsHDougadosMvan der HeijdeDAssessment of enthesitis in ankylosing spondylitisAnn Rheum Dis200362212713212525381
   PubMed Web of Science ®Google Scholar
• PappKCatherJCRosophLEfficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trialLancet201238073874622748702
   PubMed Web of Science ®Google Scholar
• GottliebABStroberBKruegerJGAn open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilastCurr Med Res Opin2008241529153818419879
   PubMed Web of Science ®Google Scholar
• PappKAKaufmannRThaçiDHuCSutherlandDRohanePEfficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison studyJ Eur Acad Dermatol Venereol2013273e376e38323030767
   PubMed Web of Science ®Google Scholar
• PalfreemanACMcNameeKEMcCannFENew developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastDrug Design Develop Ther20137201210
   PubMed Web of Science ®Google Scholar